Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Robbins LLP Urges GUTS Stockholders to Contact the Firm for Information About the Class Action Against Fractyl Health, Inc.Robbins LLP is Investigating Allegations that Fractyl Health, Inc. Misled Investors Regarding the Viability and Efficacy of its Revita DMR System
- Astellas Pharma Inc.Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer- Study evaluates novel, investigational KRAS G12D-targeted protein degrader setidegrasib versus docetaxel in previously treated patients with advanced NSCLC - - Milestone marks second Phase 3 study of setidegrasib initiated within six months - TOKYO, Sept. 23, 2026 --...
- Kaplan Fox & Kilsheimer LLPKaplan Fox Announces the Lead Plaintiff Deadline of November 2, 2026 in the Securities Class Action Against Hims & Hers Health, Inc. (HIMS)Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us. You may...
- Make Time WellnessMake Time Wellness Expands Access to Women's Brain Health with Meijer Launch and Return to QVCCompanies: QVC GroupScientific Advisor Nicole Beurkens, PhD, to Promote Brain Health Awareness on QVC as Make Time Wellness Expands Distribution to Meijer Stores — Make Time Wellness, the rapidly growing women's brain health supplement line founded by Emma Heming...
- Viking Therapeutics, Inc.Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior NotesViking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its intention to offer, subject to market and other...
- Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress"Featuring Serina Therapeutics’ CEO - Thursday, September 24, 2026
- Precision Optics Schedules Fourth Quarter and Fiscal Year 2026 Conference Call for September 28, 2026Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company’s fourth quarter and full year fiscal 2026 financial results on Monday, September 28, 2026, at 5:00 p.m. ET.
- OracleOracle to Advance Cancer Care with New Oncology EHRCompanies: Oracle CorporationOracle Health and Life Sciences Summit – Oracle today announced its Oracle Health Oncology EHR. Building on the capabilities of Oracle's modern,...
- Bauman Medical to Present New Head-to-Head Data Comparing Autologous Hair Follicle Secretome (aHFS) to PRP at ISHRS 2026 World Congress in Rio de JaneiroDr. Alan Bauman's presentation at ISHRS World will show a cell-free, patient-derived regenerative therapy substantially outperforming platelet-rich plasma
- Tampa Bay Wave Collaborates with Vanderbilt Health to Launch Dual-Region HealthTech|X Accelerator for Behavioral Health and Addiction StartupsCollaboration pairs Tampa Bay and Nashville’s healthcare ecosystems, giving founders direct access to investors, researchers, clinicians, and licensing opportunities
- University of Colorado AnschutzCU Anschutz Researchers Test Drones as a New Way to Deliver Blood Products in EmergenciesResearchers are studying whether drones can deliver freeze-dried plasma directly to critically injured patients when conventional transportation cannot get them to a hospital quickly enough, a potential new approach to emergency medical care in warzones, disasters and remote communities...
- CROSSJECT et la BARDA consolident le plan de développement pédiatrique de ZEPIZURE® selon les attentes de la FDA avec un financement renforcé jusqu’en 2030DIJON, France — 23 septembre 2026 – 19 h 00 (CEST) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), Specialty Pharma internationale spécialisée dans le développement d’auto-injecteurs sans aiguille destinés aux situations d’urgence, annonce aujourd’hui que CROSSJECT et la BARDA ont consolidé le plan de développement clinique pour l’indication pédiatrique de ZEPIZURE®, conformément aux recommandations de la FDA. En vertu de la modification n° 4 du contrat n° 75A50122C00031, la BARDA apporte un financement supplémentaire non dilutif de 4,7 millions de dollars pour couvrir ce plan et a prolongé la durée d’exécution jusqu’au 21 juin 2030. Le financement total de la BARDA consacré au développement de ZEPIZURE® s’élève désormais à 48,0 millions de dollars.